ResearcherFukushima Medical UniversityActive in the last 2 years
Yuichi Waragai
Matched on OpenAlex author ID A5064385778. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers
Papers 6
- Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17798↗
- Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. Co-author DOI 10.5387/fms.24-00011↗
- Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.23377↗
- Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. Co-author DOI 10.5387/fms.2017-04↗
- Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2016.09.003↗
- Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer. Co-author DOI 10.3892/ol.2016.4381↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mitsuru Sugimoto · 6 shared papers, 2016–2025 · strength 0.69
- Paper Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer. DOI 10.21873/anticanres.17798↗
- Paper Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. DOI 10.5387/fms.24-00011↗
- Paper Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.23377↗
- Hiromasa Ohira · 6 shared papers, 2016–2025 · strength 0.69
- Paper Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer. DOI 10.21873/anticanres.17798↗
- Paper Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. DOI 10.5387/fms.24-00011↗
- Paper Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.23377↗
- Hiroyuki Asama · 5 shared papers, 2016–2025 · strength 0.64
- Paper Development and Validation of a Nomogram of Predict Eligibility for Second-line Chemotherapy in Pancreatic Cancer. DOI 10.21873/anticanres.17798↗
- Paper Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. DOI 10.5387/fms.24-00011↗
- Paper Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.23377↗
- Rei Suzuki · 5 shared papers, 2016–2025 · strength 0.46
- Paper Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. DOI 10.5387/fms.24-00011↗
- Paper Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.23377↗
- Paper Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. DOI 10.5387/fms.2017-04↗
- Tadayuki J. Takagi · 5 shared papers, 2016–2025 · strength 0.46
- Paper Impact of COVID-19 pandemic on unresectable pancreatic cancer: a regional cohort study in Japan. DOI 10.5387/fms.24-00011↗
- Paper Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. DOI 10.18632/oncotarget.23377↗
- Paper Contrast-enhanced harmonic endoscopic ultrasonography in gallbladder cancer and pancreatic cancer. DOI 10.5387/fms.2017-04↗
- Hiroki Irie · 2 shared papers, 2025 · strength 0.45
- Hiroshi Shimizu · 2 shared papers, 2025 · strength 0.45
- Kentaro Sato · 2 shared papers, 2025 · strength 0.45
- Rei Suzuki · 1 shared paper, 2025 · strength 0.23
- Rei Ohira · 1 shared paper, 2025 · strength 0.23
- Atsushi Masamune · 2 shared papers, 2016–2018 · strength 0.12
- Shigeru Marubashi · 1 shared paper, 2018 · strength 0.07
- Ya’an Kang · 1 shared paper, 2016 · strength 0.05
- Jason B. Fleming · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.